MAY 28, 2014 10:30 AM PDT

Heavy/Light Chain Combination Assays: What Laboratories should know about M-Protein detection

Speaker
  • Senior Director of Scientific Affairs, Binding Site
    Biography
            Richard M. O'Hara, Jr. grew up in Texas.  He received a baccalaureate degree in Biology from the University of Texas at Austin.  After working as a research associate for a few years he entered the Immunology Graduate Program at The University of Texas Southwestern Medical School in Dallas, Texas.  Dr. O'Hara spent the final two years of his graduate training at Dalhousie University in Halifax Nova Scotia working with the group that established the first Liver Transplant program in the region.      Following his graduate training he and his family moved to Boston where he entered a postdoctoral training program at Harvard Medical School, working on mechanisms of T cell mediated immune regulation.  He entered the pharmaceutical industry, joining Genetics Institute (later Wyeth Research) as a research scientist in 1988.  His work on cytokine biology led to the development of two new therapeutic drugs and several US patents in hematology and oncology.  Later work in the role of costimulation in graft rejection and autoimmunity led to the development of several other drug candidates.      In 2007, after more than twenty years of research in the fields of autoimmunity and transplantation, he joined The Binding Site as Sr. Director of Scientific Affairs.  In his role at Binding Site, Dr. O'Hara has presented extensively at major US academic medical centers on the characterization on monoclonal proteins in patients with Multiple Myeloma and other Plasma Cell Dyscrasias.    

    Abstract

    Traditional testing methods for monoclonal protein in Plasma Cell Dyscrasias correctly identify a majority of patients. However, limitations in these methods can cause patients to be missed at diagnosis. Furthermore, difficulties in traditional methods of measuring monoclonal proteins have restricted the ability to measure M-proteins at low levels thereby limiting the laboratory and the clinician, particularly in identifying patients who have minimal residual disease.

    In the past decade, assays which can measure immunoglobulin free light chains has improved detection of patients with Multiple Myeloma and related diseases, as well as providing a more sensitive tool for measuring a patients response to therapy. However, that assay is limited in that not all patients with monoclonal gammopathy show abnormal free light chain measurements. Within the last year, a novel assay which can identify and quantitate individual immunoglobulin heavy chain/light chain pairs has received FDA approval. Like Immunofixation, this assay has the ability to identify m-protein heavy chain and light chain isotypes. However, unlike Immunofixation, the heavy chain/light chain combination assay is quantitative and provides information which is independent of complicating factors such as changes in hematocrit. This heavy chain/light chain combination assay shares with the free light chain assay the ability to measure the analyte in normal individuals, providing exquisite sensitivity when measuring patients in relapse or with minimal residual disease.

    The heavy chain/light chain combination assay is not intended to replace the free light chain assay but rather provides complementary information which enhances the laboratorys ability to provide quantitative information on M-protein production. Utilizing both assays,will enhance the ability of the laboratory and the clinician to evaluate patient tumor load at diagnosis and in response to therapy.


    Show Resources
    You May Also Like
    MAY 11, 2021 10:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    C.E. CREDITS
    MAY 11, 2021 10:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    Date: May 11, 2021 Time: 10:00zm PDT Your samples are some of the most valuable assets in the laboratory. After spending countless hours on extraction and preparation, your conclusions could...
    OCT 29, 2020 6:00 AM PDT
    C.E. CREDITS
    OCT 29, 2020 6:00 AM PDT
    Date: October 29, 2020 Time: 6:00am (PDT), 9:00am (EDT), Chronic inflammation can occur as a result of a combination of genetic predispositions and environmental factors. Epigenetic modifica...
    NOV 16, 2020 8:00 AM PST
    C.E. CREDITS
    NOV 16, 2020 8:00 AM PST
    Date: November 16, 2020 Time: 8:00am (PST), 11:00am (EST) CRISPR screening has become the prime discovery tool in modern biomedical research and drug discovery. At the same time, most screen...
    NOV 18, 2020 8:00 AM PST
    C.E. CREDITS
    NOV 18, 2020 8:00 AM PST
    DATE: November 18, 2020 TIME: 08:00am PDT We develop and implement technologies to solve some of the major bottlenecks in biomedical research. In particular, we establish new imaging approac...
    APR 01, 2021 8:00 AM PDT
    C.E. CREDITS
    APR 01, 2021 8:00 AM PDT
    Date: April 01, 2021 Time: 8:00am (PST), 11:00am (EST) Generating therapeutic antibodies is far more challenging than obtaining antibodies that merely recognize their targets. Engineering po...
    MAR 16, 2021 10:00 AM PDT
    C.E. CREDITS
    MAR 16, 2021 10:00 AM PDT
    Date: March 16, 2021 Time: 10:00am (PST) Scientific progress and breakthroughs today are often too expensive for most institutions to acquire. Each year, the National Institutes of Health (N...
    MAY 28, 2014 10:30 AM PDT

    Heavy/Light Chain Combination Assays: What Laboratories should know about M-Protein detection


    Specialty

    Research

    Health

    Chemistry

    Wellness

    Earth Science

    University

    Quality Control/assurance

    Infectious Disease

    Clinical Chemistry

    Personalized Medicine

    Cancer

    Clinical Toxicology

    Laboratory Testing

    Clinical Diagnostics

    Disease

    Geography

    North America67%

    Asia33%

    Registration Source

    Website Visitors100%

    Job Title

    Medical Laboratory Technician67%

    Clinical Laboratory Scientist33%

    Organization

    Hospital33%

    Manufacturer - Other33%

    Clinical Laboratory33%


    Show Resources
    Loading Comments...
    Show Resources
    Attendees
    • See more